AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01842165 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous injection of 177Lu-octreotate
Description: Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
Study NCT01967017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study NCT01967017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01229072 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Heparin sodic
Description: Heparin sodic 150UI/kg
Study NCT01229072 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: heparin liquemine
Description: Heparin sodic 150UI/kg
Study NCT05081349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide 500 Mg Oral Capsule+L-Carnitine
Description: Combination therapy
Study NCT05081349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxycarbamide 500 Mg Oral Capsule
Description: Single agent
Study NCT05081349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine, 250 Mg Oral Capsule
Description: single agent
Study NCT01477463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 4,000 IU oral vitamin D3
Study NCT01477463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo and vitamin D
Study NCT04384445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zofin
Description: Biological: Zofin will be administered intravenously with 1ml, containing 2-5 x 10\^11 particles/mL in addition to the Standard Care. The Zofin dose will be diluted in 100 mL of sterile saline at subject's bedside.
Study NCT04384445 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Other: Placebo Placebo (saline) will be administered intravenously with 1ml in addition to the Standard Care. The Placebo dose will be diluted in 100 mL of sterile saline at subject's bedside.
Study NCT02906215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Coordination Intervention
Description: cross-training in HIV/PrEP and substance use, plus a digital health tool to improve evidence-based screening, brief intervention, referral to treatment, and patient management across HIV, PrEP, and addiction treatment providers
Study NCT01235364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: The Foley catheter was placed with the digital method
Study NCT01235364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter
Description: The Foley catheter was placed with a speculum
Study NCT00825058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amibegron (SR58611A)
Description: oral administration 2 X 350mg/day at 12 hours intervals
Study NCT00825058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration 12 hours intervals
Study NCT00825058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: oral 20 mg/day
Study NCT03497546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Concurrent (aerobic and strength) supervised exercise program: the program comprises 3 sessions/week (60 min/session) of aerobic and strength exercises of progressive volume and intensity. The program will follow the Consensus on Exercise Reporting Template (CERT) guidelines.
Study NCT01215110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC207
Study NCT02241356 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bifocals
Description: bifocal glasses with an addition of 2.5 Dioptres
Study NCT02241356 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single vision glasses
Description: single vision glasses
Study NCT01697371 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton
Description: All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.~Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments
Study NCT01697371 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Radiation
Study NCT03561844 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aromatherapy
Description: Each of participants in the aromatherapy (inhalation) group will receive inhalation aromatherapy and those in the aromatherapy (massage) group will receive aromatherapeutic massage. As to the waiting control group, participants will be given either one of these two interventions after the implementation phase is completed.
Study NCT01215110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifafour e-275 mg
Study NCT02502604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
Study NCT06016595 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Chronic prostatitis/chronic pelvic pain syndrome
Description: Chronic prostatitis/chronic pelvic pain syndrome UPOINT
Study NCT02315794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPI®ART
Description: implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
Study NCT02315794 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPI®EASY
Description: implant prosthetic restoration using a commercially pure titanium grade 4 abutment
Study NCT02774863 — intervention group
Intervention type: OTHER
Intervention: Home passages
Description: Three home passages between the 2nd and 3rd months of follow up.
Study NCT03546166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Picato 0.05% Topical Gel
Description: apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days. In case of treatment failure after 3 months, apply again on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 2 consecutive days.
Study NCT05571007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True acupressure
Description: Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy.
Study NCT05571007 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupressure
Description: Duration: 3 minutes for each acupoint, applied bilaterally (right and left sides).~Total time: 18 minutes/acupressure therapy.
Study NCT01640418 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex® Border Sacrum dressings
Description: Mepilex® Border Sacrum dressings
Study NCT02970006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurovisual stimulation
Description: a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
Study NCT01626118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: capsules, 40 mg, TID
Study NCT01626118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: capsules, 40 mg, BID
Study NCT01626118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: capsules, 20 mg, TID
Study NCT01626118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules
Study NCT01173549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin/Placebo Placebo/Canagliflozin
Description: Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
Study NCT01173549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
Study NCT04527874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VITAL model
Description: The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform.~To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening.
Study NCT02638753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education
Description: Patients will be educated about pain neurophysiology.
Study NCT02638753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education combined with hypnosis
Description: Patients will be educated about pain neurophysiology combined with hypnosis.
Study NCT05370560 — intervention group
Intervention type: OTHER
Intervention: Plasma transthyretin concentration
Description: Plasma transthyretin concentrations were measured by BS 200 Autoanalyser (Mindray, Shenzhen, China) using immunoturbidimetric method.
Study NCT02425813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Given PO
Study NCT02425813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Sodium Succinate
Description: Given IA and IV
Study NCT02291302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: integrated pest management
Description: integrated pest management and environmental strategy
Study NCT02291302 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: integrated pest management
Description: integrated pest management and environmental strategy
Study NCT02291302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: air purifier
Description: air purifiers
Study NCT02291302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: air purifier
Description: air purifiers
Study NCT02291302 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention (control)
Description: no integrated pest management and sham air purifier
Study NCT04660292 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland's mobilization
Description: Maitland's techniques involve the application of passive and accessory oscillatory movements to spinal and vertebral joints to treat pain and stiffness.It has Five grades
Study NCT04660292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical therapy
Description: BASELINE TREATMENT INCLUDES TENS and Hot PACKS
Study NCT03848208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisine
Description: cytisine film-coated oral tablet
Study NCT02018276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
Study NCT02018276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium
Description: The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
Study NCT01807676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ET View Double Lumen Tube
Study NCT04174079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: patients with R0 resected T≥3 or N≥1 thoracic esophageal squamous cell carcinoma began to receive chemotherapy of docetaxel combined with nedaplatin within 8 weeks after total two-field lymph node dissection. Docetaxel 75mg/m2 day 1, nedaplatin 75mg/m2 day 1, every 21 days for 4 cycles
Study NCT02760654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive Self Management Program for Effects of Cancer Treatment
Study NCT00786864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise programme
Description: Specific low back pain exercise programme for children
Study NCT03115099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3325656
Description: Administered orally
Study NCT03115099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03115099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Administered subcutaneously
Study NCT03115099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Administered orally
Study NCT04515992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Body-weight Circuit Training (HIBC)
Description: HIBC Exercise Protocol- The HIBC circuit repetition and order is as follows: modified squats (10 repetitions), modified rows (5 repetitions), crunches (10 repetitions), and modified push-ups (5 repetitions). The exercise sessions involved repeating a series of repetitions of each movement in sequence, and completing as many sequences as possible in good form in the time allotted for the exercise (initially, 5 minutes). Participants were instructed to complete three sessions per week and documented the number of cycles completed. After 3 weeks of consistent training, participants were asked to add a 4th session each week as tolerated. Initially, the HIBC sessions were 5 minutes long, and the duration of the sessions were increased by one minute each week as tolerated beginning in week four, peaking at 10-minutes per session as early as the eighth week of training. Session duration was capped at 10 minutes.
Study NCT04501744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 of M701
Description: Patients in Cohort 1 will receive 4 escalating doses (2, 5, 10 and 25 μg) of M701 on Days 1, 8, 15 and 22. The maintenance dose during extended treatment period is 25 μg.
Study NCT04501744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 of M701
Description: Patients in Cohort 2 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 25 μg, and the maintenance dose during core treatment period and extended treatment period is 50 μg.
Study NCT04501744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 of M701
Description: Patients in Cohort 3 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 50 μg, and the maintenance dose during core treatment period and extended treatment period is 100 μg.
Study NCT04501744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4 of M701
Description: Patients in Cohort 4 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 100 μg, and the maintenance dose during core treatment period and extended treatment period is 200 μg.
Study NCT04501744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 5 of M701
Description: Patients in Cohort 5 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 150 μg, and the maintenance dose during core treatment period and extended treatment period is 300 μg.
Study NCT04501744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 6 of M701
Description: Patients in Cohort 6 will receive a starting dose on Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 200 μg, and the maintenance dose during core treatment period and extended treatment period is 400 μg.
Study NCT04501744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 7 of M701
Description: Patients in Cohort 7 will receive a starting doseon Day 1 and three infusions at a higher maintenance dose level on Days 8, 15 and 22. The starting dose is 250 μg, and the maintenance dose during core treatment period and extended treatment period is 500 μg.
Study NCT01308684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5323441 + bevacizumab [Avastin]
Description: Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
Study NCT01308684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
Study NCT00447837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPRC-AB01
Description: 90 mg/3 mL BID, 180 mg/3 mL bid, placebo
Study NCT00447837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPRC-AB01
Description: 90 mg/3 mL BID, 180 mg/3 mL bid, placebo
Study NCT02198417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER
Description: Treatment with metformin ER for 12 weeks
Study NCT02261805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Study NCT02261805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT00981552 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: IMRT planning
Study NCT00981552 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 4-Field Radiation Planning
Study NCT03827200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: Ambrisentan will be administered subcutaneously at the Hospital on the days of HVPG deterination and taken orally at home between visits.
Study NCT01792557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystallized phenol
Description: Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
Study NCT01792557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Limberg Flap
Description: Limberg Flap surgery for pilonidal disease treatment
Study NCT01792557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Limberg Flap
Description: Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
Study NCT01792557 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Karydakis Flap
Description: Karydakis Flap surgery for pilonidal disease treatment
Study NCT00846222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
Study NCT04425980 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Constraint-Induced Movement Therapy
Description: intensive use of more affected arm in structured setting
Study NCT04425980 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy
Description: intensive use of more affected arm in structured setting
Study NCT03806309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2
Study NCT03806309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Intravenous (IV); folinic acid 400 mg/m\^2, irinotecan 180 mg/m\^2, 5-FU bolus 400 mg/m\^2 and continuous infusion 2,400 mg/m\^2
Study NCT03806309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSE2101
Description: subcutaneous injection on days 1 and 15, every 4 weeks for 6 doses then every 8 weeks until month 12 and then every 12 weeks for a maximum treatment duration of 24 months
Study NCT02134171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological and imaging investigations
Description: From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide \[BNP\]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
Study NCT02394054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin
Description: Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).